Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 11 - 20 of about 175   

Articles published

GSK 1,449.32 +12.82 (0.89%)
price chart
Will GlaxoSmithKline plc's Vaccine Stop Ebola?
GlaxoSmithKline plc (LSE: GSK) is leading the race to try and find a vaccine that will stop the advance of the deadly Ebola virus, which is currently spreading across West Africa.
GlaxoSmithKline plc (ADR) (NYSE:GSK) and NIH Spearheading Development of ...  BasicsMedia
Ebola Vaccine: First-Ever Human Trials For Experimental Drug To Begin Soon  International Business Times
Related articles »  
Why You Should Let GlaxoSmithKline plc Look After Your Money
One such company is GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). In the middle of last year, Chinese authorities announced that in recent years GlaxoSmithKline used hundreds of travel agencies and consulting firms to funnel nearly three billion yuan in ...
Related articles »  
GlaxoSmithKline plc Stock Rating Reaffirmed by Jefferies Group (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its �hold� rating reaffirmed by analysts at Jefferies Group in a research report issued to clients and investors on Monday.
GlaxoSmithKline plc Earns Hold Rating from Jefferies Group (GSK)  Intercooler
GlaxoSmithKline plc Given Neutral Rating at JPMorgan Chase & Co. (GSK)  Watch List News (press release)
Related articles »  
1 Reason I Wouldn't Buy GlaxoSmithKline plc Today
GlaxoSmithKline remains stuck between a rock and a hard place as allegations of improper conduct spread across its global operations continue to grow.
Related articles »  
3 Great Shares For A Beginners' Portfolio: GlaxoSmithKline plc, Schroders plc ...
gsk Multi-billionaire Warren Buffett, probably the world's most famous and successful investor, follows a strategy of buying great businesses with a view to holding his shares 'forever'.
Is GlaxoSmithKline plc's Opportunity AstraZeneca plc's Threat?
There are no two better examples of this fact than the case of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and AstraZeneca (LSE: AZN) (NYSE: AZN.
GlaxoSmithKline plc Could Be Worth 1690p!
GlaxoSmithKline Investors in GlaxoSmithKline (LSE: GSK) have had a truly dismal 2014. Shares in the pharmaceutical company are down 12% since the turn of the year, with the FTSE 100 being flat over the same time period.
My Favourite 5%+ Yields: GlaxoSmithKline plc, Centrica PLC & Vodafone Group ...
GlaxoSmithKline (LSE: GSK) continues to see its share price underperform due to weak sentiment rather than doubts surrounding its long term potential.
Related articles »  
The Benefits Of Investing In GlaxoSmithKline plc
Ongoing fears over corruption allegations across the world has dominated investor sentiment towards medicine giant GlaxoSmithKline during the past 12 months. The share price has failed to gain significant traction as a result, and the firm has ...
GlaxoSmithKline plc Given Consensus Recommendation of "Hold" by ...  Ticker Report
Related articles »  
Here's Why You Need GlaxoSmithKline plc In Your Portfolio
There's no doubt that GlaxoSmithKline's (LSE: GSK) (NYSE: GSK.US) future is uncertain. After being accused of using bribes to sell its treatments within several markets, the biotechnology giant is now under investigation by the Serious Fraud Office.